Pharvaris BV Market Cap ($2.41 Billion)
Market Cap & Net Worth: Pharvaris BV (PHVS)
Pharvaris BV market cap. Pharvaris BV (NASDAQ:PHVS) has a market capitalization of $2.41 Billion ($2.41 Billion) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #5409 globally and #1803 in its home market, demonstrating a 7.45% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pharvaris BV's stock price $34.33 by its total outstanding shares 70204506 (70.20 Million). Also see Pharvaris BV (PHVS) cash flow conversion for how efficiently the company converts equity into cash flow.
Pharvaris BV Market Cap History (2021–2026)
Pharvaris BV market cap history from 2021 to 2026. Data shows growth from $1.01 Billion to $2.41 Billion (2.98% CAGR). Check Pharvaris BV stock price for real-time trading data and today's change.
Index Memberships
Pharvaris BV is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.09% | #145 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.01% | #617 of 3165 |
Weight: Pharvaris BV's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Pharvaris BV Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pharvaris BV's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Pharvaris BV growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PHVS by Market Capitalization
Companies near Pharvaris BV in the global market cap rankings as of November 5, 2026. Also see Pharvaris BV total assets for a full breakdown of the balance sheet.
Key companies related to Pharvaris BV by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Pharvaris BV (2021–2026)
Market capitalization of Pharvaris BV from 2021 to today. Between 2021 and today, Pharvaris BV's market cap moved from $1.01 Billion to $ 2.41 Billion, with a yearly change of 2.98%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.41 Billion | +23.71% |
| 2025 | $1.95 Billion | +44.76% |
| 2024 | $1.35 Billion | -31.66% |
| 2023 | $1.97 Billion | +149.33% |
| 2022 | $789.80 Million | -21.82% |
| 2021 | $1.01 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Pharvaris BV was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.41 Billion USD |
| MoneyControl | $2.41 Billion USD |
| MarketWatch | $2.41 Billion USD |
| marketcap.company | $2.41 Billion USD |
| Reuters | $2.41 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Pharvaris BV
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and a… Read more